These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 29336929)

  • 1. Economic burden and cost-effective management of Clostridium difficile infections.
    Heimann SM; Cruz Aguilar MR; Mellinghof S; Vehreschild MJGT
    Med Mal Infect; 2018 Feb; 48(1):23-29. PubMed ID: 29336929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis.
    Konijeti GG; Sauk J; Shrime MG; Gupta M; Ananthakrishnan AN
    Clin Infect Dis; 2014 Jun; 58(11):1507-14. PubMed ID: 24692533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal Transplants by Colonoscopy and Capsules Are Cost-Effective Strategies for Treating Recurrent Clostridioides difficile Infection.
    Luo Y; Lucas AL; Grinspan AM
    Dig Dis Sci; 2020 Apr; 65(4):1125-1133. PubMed ID: 31493042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Competing Treatment Strategies for Clostridium difficile Infection: A Systematic Review.
    Le P; Nghiem VT; Mullen PD; Deshpande A
    Infect Control Hosp Epidemiol; 2018 Apr; 39(4):412-424. PubMed ID: 29463339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection in Australia.
    Merlo G; Graves N; Brain D; Connelly LB
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1927-1932. PubMed ID: 27043242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of treatment strategies for initial Clostridium difficile infection.
    Varier RU; Biltaji E; Smith KJ; Roberts MS; Jensen MK; LaFleur J; Nelson RE
    Clin Microbiol Infect; 2014 Dec; 20(12):1343-51. PubMed ID: 25366338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France.
    Watt M; Dinh A; Le Monnier A; Tilleul P
    J Med Econ; 2017 Jul; 20(7):678-686. PubMed ID: 28299963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease.
    You JHS; Jiang X; Lee WH; Chan PKS; Ng SC
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1515-1523. PubMed ID: 32017248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of Fecal Microbiota Transplantation for First Recurrent Clostridioides difficile Infection.
    Aby ES; Vaughn BP; Enns EA; Rajasingham R
    Clin Infect Dis; 2022 Oct; 75(9):1602-1609. PubMed ID: 35275989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness Analysis of Five Competing Strategies for the Management of Multiple Recurrent Community-Onset Clostridium difficile Infection in France.
    Baro E; Galperine T; Denies F; Lannoy D; Lenne X; Odou P; Guery B; Dervaux B
    PLoS One; 2017; 12(1):e0170258. PubMed ID: 28103289
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Asempa TE; Nicolau DP
    Clin Interv Aging; 2017; 12():1799-1809. PubMed ID: 29123385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Comprehensive Study of Costs Associated With Recurrent Clostridium difficile Infection.
    Rodrigues R; Barber GE; Ananthakrishnan AN
    Infect Control Hosp Epidemiol; 2017 Feb; 38(2):196-202. PubMed ID: 27817758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Navigating changes in
    Durham SH; Le P; Cassano AT
    J Manag Care Spec Pharm; 2020 Dec; 26(12-a Suppl):S3-S23. PubMed ID: 33533699
    [No Abstract]   [Full Text] [Related]  

  • 14. Economic Burden of Clostridium difficile Infection in European Countries.
    Reigadas Ramírez E; Bouza ES
    Adv Exp Med Biol; 2018; 1050():1-12. PubMed ID: 29383660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of Treatment Regimens for Clostridioides difficile Infection: An Evaluation of the 2018 Infectious Diseases Society of America Guidelines.
    Rajasingham R; Enns EA; Khoruts A; Vaughn BP
    Clin Infect Dis; 2020 Feb; 70(5):754-762. PubMed ID: 31001619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of initial treatment strategies for mild-to-moderate
    Ford DC; Schroeder MC; Ince D; Ernst EJ
    Am J Health Syst Pharm; 2018 Aug; 75(15):1110-1121. PubMed ID: 29903711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful therapy of Clostridium difficile infection with fecal microbiota transplantation.
    Konturek PC; Koziel J; Dieterich W; Haziri D; Wirtz S; Glowczyk I; Konturek K; Neurath MF; Zopf Y
    J Physiol Pharmacol; 2016 Dec; 67(6):859-866. PubMed ID: 28195066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clostridium difficile infection: current, forgotten and emerging treatment options.
    Drekonja DM
    J Comp Eff Res; 2014 Sep; 3(5):547-57. PubMed ID: 25350805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term Follow-up Study of Fecal Microbiota Transplantation for Severe and/or Complicated Clostridium difficile Infection: A Multicenter Experience.
    Aroniadis OC; Brandt LJ; Greenberg A; Borody T; Kelly CR; Mellow M; Surawicz C; Cagle L; Neshatian L; Stollman N; Giovanelli A; Ray A; Smith R
    J Clin Gastroenterol; 2016; 50(5):398-402. PubMed ID: 26125460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of three different strategies for the treatment of first recurrent Clostridium difficile infection diagnosed in a community setting.
    Lam SW; Neuner EA; Fraser TG; Delgado D; Chalfin DB
    Infect Control Hosp Epidemiol; 2018 Aug; 39(8):924-930. PubMed ID: 29961435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.